AA

References

Download as a PDF

Amendola MA, Shirazi K, Amendola BE, Kuhns LR, Tisnado J, Yaghmai I. Computed tomography of malignant tumors of the osseous pelvis. Comput.Radiol 1983;7:107-117.

Aubut JL, Mehta S, Cullen N, Teasell RW, ERABI Group, the SCIRE research team. A comparison of heterotopic ossification treatment within the traumatic brain and spinal cord injured population: An evidence based systematic review. Neuro Rehabil 2011; 28: 151-160.

Banovac K, Gonzalez F, Wade N, Bowker JJ. Intravenous disodium etidronate therapy in spinal cord injury patients with heterotopic ossification. Paraplegia 1993;31:660-666.

Banovac K, Gonzalez F, Evaluation and management of heterotopic ossification in patients with spinal cord injury. Spinal Cord1997;35:158-162.

Banovac K, Gonzalez F, Renfree KJ. Treatment of heterotopic ossification after spinal cord injury. J Spinal Cord Med1997;20:60-65.

Banovac K, The effect of etidronate on late development of heterotopic ossification after spinal cord injury. The Journal of Spinal Cord Medicine 2000;23:40-44.

Banovac K, Williams JM, Patrick LD, Haniff YM. Prevention of heterotopic ossification after spinal cord injury with indomethacin. Spinal Cord 2001;39:370-374.

Banovac K, Williams JM, Patrick LD, Levi A. Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). Spinal Cord 2004;42:707-710.

Buschbacher R, McKinley W, Buschbacher L, Devaney CW, Coplin B. Warfarin in prevention of heterotopic  ossification. Am J Phys Med Rehabil1992;71:86-91.

Chalmers J, Gray DH, Rush J. Observations on the induction of bone in soft tissues. J Bone Joint Surg Br 1975;57:36-45.

Citak M, Suero EM, Backhaus M, Aach M, Godry H, Meindl R, Schildhauer TA. Risk factors for heterotopic ossification in patients with spinal cord injury: A case-control study of 264 patients. Spine. 2012;37(23):1953-1957.

Durovic A, Miljkovic D, Brdareski Z, Plavsic A, Jevtic M. Pulse low intensity electromagnetic field as prophylaxis of heterotopic ossification in patients with traumatic spinal cord injury. Vojnosanit Pregl 2009;66:22–28.

Finerman GA, Stover SL. Heterotopic ossification following hip replacement or spinal cord injury. Two clinical studies with EHPD. Metab Bone Dis Rel Res1981;3:337-342.

Fleisch H. Biphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991;42:919-944.

Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Sci 1969;165:1262-1264.

Freed JH, Hahn H, Menter R, Dillon T. The use of the three-phase bone scan in the early diagnosis of heterotopic ossification (HO) and in the evaluation of didronel therapy. Paraplegia 1982;208-216.

Garland DE, Orwin JF. Resection of heterotopic ossification in patients with spinal cord injuries. Clin Orthop Relat Res 1989; 242: 169-276.

Garland DE, Alday B, Venos KG, and Vogt JC. Diphosphonate treatment for heterotopic ossification in spinal cord injury patients. Clinical orthopaedics and related research 1983;176:197-200.

Garland DE, Thompson R, Waters RL. Musculocutaneous neurectomy for spastic elbow flexion in non-functional upper extremities in adults. J Bone Joint Surg Am 1980;62:108-112.

Genet F, Jourdan C, Lautridou C, Chehensse C, Minooee K, Denormandie P, Schnitzler A. The Impact of Preoperative Hip Heterotopic Ossification Extent on Recurrence in Patients with Head and Spinal Cord Injury: A  Case Control Study. PLoS ONE 2011; 6(8): e23129.

Hurvitz EA, Mandac BR, Davidoff G, Johnson JH, Nelson VS. Risk factors for heterotopic ossification in children and adolescents with severe traumatic brain injury. Arch Phys Med Rehabil 1992;73:459-462.

Mavrogenis AF, Guerra G, Staals EL, Bianchi G, Ruggieri P. A classification method for neurogenic heterotopic ossification of the hip. J Orthop Traumatol 2012;13(2):69-78.

Meiners T, Abel R, Bohm V, Gerner HJ. Resection of heterotopic ossification of the hip in spinal cord injured patients. Spinal Cord 1997;35:443-445.

Neal B. Effects of heterotopic bone formation on outcome after hip arthroplasty. A J Surg 2003;73:422-426.

Orzel JA, Rudd TG. Heterotopic bone formation: clinical, laboratory, and imaging correlation. J Nucl Med 1985;26:125-132.

Pape HC, Lehmann U, van GM, Gansslen A, von GS, Krettek C. Heterotopic ossifications in patients after severe blunt trauma with and without head trauma: incidence and patterns of distribution. J Orthop Trauma 2001;15:229-237.

Pape HC, Marsh S, Morley JR, Krettek C, Giannoudis PV. Current concepts in the development of heterotopic ossification. J Bone Joint Surg Br 2004;86:783-787.

Puzas JE, Evarts CM, Brand JS. The stimulus for bone formation. Hip 1987;25-38.

Rossier AB, Bussat P, Infante F, Zender R, Courvoisier B, Muhelm G et al. Current facts of para-osteo-arthropathy (POA). Paraplegia 1973;11(1):38-78.

Sautter-Bihl ML, Hultenschmidt B, Liebermeister E, Nanassy A Fractionated and single-dose radiotherapy for heterotopic bone formation in patients with spinal cord injury. A phase-I/II study, Strahlenther Onkol 2001;177:200-205.

Sautter-Bihl ML, Liebermeister E, Nanassy A. Radiotherapy as a local treatment option for heterotopic ossifications in patients with spinal cord injury. Spinal Cord 2000;38:33-36.

Schurch B, Capaul M, Vallotton MB, Rossier AB. Prostaglandin E2 measurements: Their value in the early diagnosis of heterotopic ossification in spinal cord injury patients. Arch Phys Med Rehabil 1997;78(7):687-691.

Schuetz P, Mueller B, Christ-Crain M, Dick W, Haas H. Amino-biphosphonates in heterotopic ossification: first experience in five consecutive cases. Spinal Cord 2005;43:604-610.

Shehab D. Elgazzar AH, Collier BD. Heterotopic ossification. J Nucl Med 2002;43:346-353.

Singh RS, Craig MC, Katholi CR, Jackson AB, Mountz JM. The predictive value of creatine phosphokinase and alkaline phosphatase in identification of heterotopic ossification in patients after spinal cord injury. Arch Phys Med Rehabil 2003;84(11):1584-1588.

Smith R. Fibrodysplasia (myositis) ossificans progressive. Clinical lessons learned from a rare disease. Clin Orthop 1998;346:7-14.

Stover SL. Didtonel in the prevention of heterotopic ossification following spinal cord injury: Determination of an optimal treatment schedule. Rehabil R D Prog Rep 1987;25:110-111.

Subbarao JV, Nemchausky BA, Gratzer M, Hines E. Resection of heterotopic ossification and didronel therapy regaining wheelchair independence in the spinal cord injured patient. J AM Paraplegia Soc 1987;10:3-7.

Teasell RW, Mehta S, Aubut JL, Ashe MC, Sequeira K, Macaluso S, Tu L, SCIRE research team. A systematic review of the therapeutic interventions for heterotopic ossification after spinal cord injury. Spinal Cord 2010;48:512-521.

Thomas BJ, Amstutz HC. Prevention of heterotopic bone formation: clinical experience with diphosphonates. Hip 1987;59-69.

Tibone J, Sakimura I, Nickel VL, Hsu JD. Heterotopic ossification around the hip in spinal cord-injured patients. A long-term follow-up study. J Bone Joint Surg Am 1978;60(6):769-775.

van Kuijk AA, Geurts AC, van Kuppevelt HJ. Neurogenic ossification in spinal cord injury. Spinal Cord 2002;40:313-326.

Welch K, Goldberg D. Serum creatine phosphokinase in motor neuron disease. Neurol 1973;22:697-701.

Williams JT, Southerland SS, Souza J, Calcutt AF, Cartledge RG. Cells isolated from adult human skeletal muscle capable of differentiating into multiple mesodermal phenotypes. Am Surg 1999;65:22-26.

Zychowicz ME. Pathophysiology of heterotopic ossification. Orthop Nurs 2013;32:173-177.